Logo image of XOMA

XOMA ROYALTY CORPORATION (XOMA) Stock Overview

NASDAQ:XOMA - US98419J2069 - Common Stock

34.86 USD
+0.1 (+0.29%)
Last: 9/3/2025, 8:00:02 PM
34.86 USD
0 (0%)
After Hours: 9/3/2025, 8:00:02 PM

XOMA Key Statistics, Chart & Performance

Key Statistics
52 Week High35.71
52 Week Low18.35
Market Cap421.46M
Shares12.09M
Float11.93M
Yearly Dividend0.47
Dividend YieldN/A
EPS(TTM)-1.54
PEN/A
Fwd PE192.36
Earnings (Next)11-05 2025-11-05
IPO06-06 1986-06-06
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


XOMA short term performance overview.The bars show the price performance of XOMA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

XOMA long term performance overview.The bars show the price performance of XOMA in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100

The current stock price of XOMA is 34.86 USD. In the past month the price increased by 22.57%. In the past year, price increased by 27.79%.

XOMA ROYALTY CORPORATION / XOMA Daily stock chart

XOMA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.01 374.26B
AMGN AMGEN INC 13.01 152.81B
GILD GILEAD SCIENCES INC 14.6 140.20B
VRTX VERTEX PHARMACEUTICALS INC 23.41 101.69B
REGN REGENERON PHARMACEUTICALS 12.35 59.76B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.65B
ARGX ARGENX SE - ADR 77.89 44.19B
ONC BEONE MEDICINES LTD-ADR 6.78 39.97B
INSM INSMED INC N/A 30.33B
BNTX BIONTECH SE-ADR N/A 24.14B
NTRA NATERA INC N/A 22.99B
BIIB BIOGEN INC 8.85 20.76B

About XOMA

Company Profile

XOMA logo image XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others. The firm also acquires milestone and royalty revenue streams on late-stage or commercial assets.

Company Info

XOMA ROYALTY CORPORATION

2200 Powell Street, Suite 310

Emeryville CALIFORNIA 94608 US

CEO: James Neal

Employees: 13

XOMA Company Website

XOMA Investor Relations

Phone: 15102047239

XOMA ROYALTY CORPORATION / XOMA FAQ

What is the stock price of XOMA ROYALTY CORPORATION today?

The current stock price of XOMA is 34.86 USD. The price increased by 0.29% in the last trading session.


What is the ticker symbol for XOMA ROYALTY CORPORATION stock?

The exchange symbol of XOMA ROYALTY CORPORATION is XOMA and it is listed on the Nasdaq exchange.


On which exchange is XOMA stock listed?

XOMA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for XOMA ROYALTY CORPORATION stock?

10 analysts have analysed XOMA and the average price target is 65.96 USD. This implies a price increase of 89.21% is expected in the next year compared to the current price of 34.86. Check the XOMA ROYALTY CORPORATION stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is XOMA ROYALTY CORPORATION worth?

XOMA ROYALTY CORPORATION (XOMA) has a market capitalization of 421.46M USD. This makes XOMA a Small Cap stock.


How many employees does XOMA ROYALTY CORPORATION have?

XOMA ROYALTY CORPORATION (XOMA) currently has 13 employees.


What are the support and resistance levels for XOMA ROYALTY CORPORATION (XOMA) stock?

XOMA ROYALTY CORPORATION (XOMA) has a support level at 32.46 and a resistance level at 34.87. Check the full technical report for a detailed analysis of XOMA support and resistance levels.


Is XOMA ROYALTY CORPORATION (XOMA) expected to grow?

The Revenue of XOMA ROYALTY CORPORATION (XOMA) is expected to grow by 78.53% in the next year. Check the estimates tab for more information on the XOMA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy XOMA ROYALTY CORPORATION (XOMA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does XOMA ROYALTY CORPORATION (XOMA) stock pay dividends?

XOMA does not pay a dividend.


When does XOMA ROYALTY CORPORATION (XOMA) report earnings?

XOMA ROYALTY CORPORATION (XOMA) will report earnings on 2025-11-05.


What is the Price/Earnings (PE) ratio of XOMA ROYALTY CORPORATION (XOMA)?

XOMA ROYALTY CORPORATION (XOMA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).


What is the Short Interest ratio of XOMA ROYALTY CORPORATION (XOMA) stock?

The outstanding short interest for XOMA ROYALTY CORPORATION (XOMA) is 2.49% of its float. Check the ownership tab for more information on the XOMA short interest.


XOMA Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to XOMA. When comparing the yearly performance of all stocks, XOMA is one of the better performing stocks in the market, outperforming 86.79% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

XOMA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to XOMA. There are concerns on the financial health of XOMA while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XOMA Financial Highlights

Over the last trailing twelve months XOMA reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS decreased by -38.74% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -7.93%
ROE -19.17%
Debt/Equity 1.11
Chartmill High Growth Momentum
EPS Q2Q%-47.62%
Sales Q2Q%18.39%
EPS 1Y (TTM)-38.74%
Revenue 1Y (TTM)168.71%

XOMA Forecast & Estimates

10 analysts have analysed XOMA and the average price target is 65.96 USD. This implies a price increase of 89.21% is expected in the next year compared to the current price of 34.86.

For the next year, analysts expect an EPS growth of 117.66% and a revenue growth 78.53% for XOMA


Analysts
Analysts82
Price Target65.96 (89.21%)
EPS Next Y117.66%
Revenue Next Year78.53%

XOMA Ownership

Ownership
Inst Owners62.65%
Ins Owners1.34%
Short Float %2.49%
Short Ratio5